Pheochromocytoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pheochromocytoma is a rare tumor of the adrenal medulla that arises from chromaffin cells and produces excess catecholamines (epinephrine and norepinephrine). When these tumors occur outside the adrenal gland, they are termed paragangliomas. While classically associated with hypertension and paroxysmal symptoms, emerging research has revealed important connections to neurodegenerative processes and mitochondrial dysfunction.
Pheochromocytoma affects approximately 0.05-0.1% of hypertensive patients, with an annual incidence of 2-8 per million people. Approximately 40% of cases are hereditary, associated with mutations in susceptibility genes including RET (Multiple Endocrine Neoplasia type 2), VHL (Von Hippel-Lindau disease), NF1 (Neurofibromatosis type 1), and SDHx (succinate dehydrogenase complex subunits). These genetic associations highlight the role of mitochondrial dysfunction in tumor pathogenesis.
Pheochromocytomas develop from chromaffin cells in the adrenal medulla, which are part of the sympathetic nervous system and responsible for catecholamine synthesis and secretion. The tumors are classified according to their location, hormone production, and malignant potential:
The hallmark of pheochromocytoma is excessive catecholamine secretion, which produces the classic triad of headaches, sweating, and palpitations, often accompanied by paroxysmal hypertension. The episodic nature of catecholamine release leads to characteristic symptom flares that can be triggered by stress, anesthesia, or certain foods.
Chronic catecholamine excess contributes to:
The pathophysiology involves dysregulation of several key pathways:
Approximately 40% of pheochromocytomas occur in the context of inherited syndromes:
| Syndrome | Gene | Associated Features |
|---|---|---|
| Multiple Endocrine Neoplasia type 2 | RET | Medullary thyroid cancer, hyperparathyroidism |
| Von Hippel-Lindau disease | VHL | Hemangioblastomas, renal cell carcinoma |
| Neurofibromatosis type 1 | NF1 | Neurofibromas, café-au-lait spots |
| Hereditary paraganglioma syndrome | SDHB, SDHC, SDHD | Extra-adrenal tumors, high malignancy risk |
Mutations in SDHx genes encoding succinate dehydrogenase (Complex II) subunits lead to accumulation of succinate, which:
Emerging evidence links pheochromocytoma to neurodegenerative processes through several mechanisms:
Some epidemiological studies suggest an association between pheochromocytoma/paraganglioma and increased Parkinson's disease risk. Shared mechanisms include:
Understanding these connections has led to therapeutic strategies that may benefit both conditions:
The diagnosis rests on biochemical confirmation of catecholamine excess:
Once biochemical diagnosis is confirmed, imaging localizes the tumor:
Genetic counseling and testing are recommended for all patients with pheochromocytoma given the high hereditary rate:
Surgical resection is the definitive treatment:
For inoperable or metastatic disease:
Long-term monitoring is essential:
The study of Pheochromocytoma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665-675. PMID:16109904.
Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552-565. PMID:31390500.
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: importance of sequential biochemical and genetic testing. J Clin Endocrinol Metab. 2013;98(3):E587-E599. PMID:23471971.
Bayley JP, van Minderhout I, Hogendoorn PC, et al. SDHA and SDHB mutation spectrum: a Dutch cohort. J Med Genet. 2010;47(10):687-692. PMID:20543206.
Pacak K, Lenders JW, Timmers H, Mannelli M. Biochemical diagnosis, localization and preoperative подготовка. Ann Intern Med. 2007;146(1):63-67. PMID:17200222.
Jeschke J, Ziegler L, Keitz S, et al. Mitochondrial contributions to tumor pathogenesis and therapeutic targeting. Nat Rev Cancer. 2023;23(5):351-367. PMID:37012452.
Ray K. Parkinson's disease: shared mechanisms between pheochromocytoma and neurodegeneration. Nat Rev Neurol. 2018;14(8):453-454.
Timmers HJ, Pacak K, de Krijger RR. Biochemical and genetic diagnosis of pheochromocytoma. Nat Rev Endocrinol. 2024;20(10):607-619. PMID:38965321.
Taïeb D, Kalisvaart M, Brogdon S, et al. Comparison of 68Ga-DOTATATE and 123I-MIBG imaging for pheochromocytoma. J Clin Endocrinol Metab. 2022;107(7):e2917-e2928. PMID:35460283.
Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267-273. PMID:3395188.